“…A number of reports show that CD and UC patients have increased titers of antibodies against E. coli, aerobes, anaerobes and even enteric bacterial pathogens, and that these antibodies are of both systemic and mucosal origin (Monteiro et al, 1971;Tabaqchali et al, 1978;Blaser et al, 1984;Macpherson et al, 1996). The previously discussed ASCA in CD patients probably reflect the same type of broad anti-microbial reactivity associated with IBD (McKenzie et al, 1990;Giaffer et al, 1992). More recently, novel gut bacterial antigens have been reported in association with IBD, including the Pseudomonas fluorescens-associated sequence I2, the outer membrane porin C of E. coli (OmpC), and bacterial flagellins, towards which CD patients develop significantly higher antibody titers than UC or control subjects (Sutton et al, 2000;Landers et al, 2002;Lodes et al, 2004).…”